346 related articles for article (PubMed ID: 11761908)
21. [Vesical sphincter disorders in Parkinson disease].
Aranda B
Rev Neurol (Paris); 1993; 149(8-9):476-80. PubMed ID: 8009145
[TBL] [Abstract][Full Text] [Related]
22. Subthalamic stimulation modulates cortical control of urinary bladder in Parkinson's disease.
Herzog J; Weiss PH; Assmus A; Wefer B; Seif C; Braun PM; Herzog H; Volkmann J; Deuschl G; Fink GR
Brain; 2006 Dec; 129(Pt 12):3366-75. PubMed ID: 17077105
[TBL] [Abstract][Full Text] [Related]
23. Bruxism as presenting feature of Parkinson's disease.
Srivastava T; Ahuja M; Srivastava M; Trivedi A
J Assoc Physicians India; 2002 Mar; 50():457. PubMed ID: 11922248
[No Abstract] [Full Text] [Related]
24. [Bladder sphincter disorders in Parkinson's disease].
Aranda B; Perrigot M; Mazières L; Pierrot-Deseilligny E
Rev Neurol (Paris); 1983; 139(4):283-8. PubMed ID: 6612141
[TBL] [Abstract][Full Text] [Related]
25. Micturition disturbance in Parkinson's disease.
Fitzmaurice H; Fowler CJ; Rickards D; Kirby RS; Quinn NP; Marsden CD; Milroy EJ; Turner-Warwick RT
Br J Urol; 1985 Dec; 57(6):652-6. PubMed ID: 4084724
[TBL] [Abstract][Full Text] [Related]
26. 3-O-Methyldopa in Parkinson's disease.
Muenter MD; Sharpless NS; Tyce GM
Adv Neurol; 1974; 5():309-15. PubMed ID: 4440579
[No Abstract] [Full Text] [Related]
27. Levodopa therapeutics for Parkinson's disease: new developments.
LeWitt PA
Parkinsonism Relat Disord; 2009 Jan; 15 Suppl 1():S31-4. PubMed ID: 19131040
[TBL] [Abstract][Full Text] [Related]
28. Facilitated temporal summation of pain at spinal level in Parkinson's disease.
Perrotta A; Sandrini G; Serrao M; Buscone S; Tassorelli C; Tinazzi M; Zangaglia R; Pacchetti C; Bartolo M; Pierelli F; Martignoni E
Mov Disord; 2011 Feb; 26(3):442-8. PubMed ID: 21462260
[TBL] [Abstract][Full Text] [Related]
29. Patient-perceived involvement and satisfaction in Parkinson's disease: effect on therapy decisions and quality of life.
Grosset KA; Grosset DG
Mov Disord; 2005 May; 20(5):616-9. PubMed ID: 15719417
[TBL] [Abstract][Full Text] [Related]
30. [Comparative assessment of combined therapy of neurogenic hyperactivity of detrusor in patients with Parkinson's disease].
Loran OB; Fedorova NV; Mazurenko DA; Khitarishvili EV
Urologiia; 2006; (2):37-9, 41. PubMed ID: 16708587
[TBL] [Abstract][Full Text] [Related]
31. [Mechanism of the development of akinesia in Parkinson's disease --with reference to L-threo-DOPS therapy].
Narabayashi H
No To Shinkei; 1983 Nov; 35(11):1057-63. PubMed ID: 6362685
[No Abstract] [Full Text] [Related]
32. Bilateral deep brain stimulation in Parkinson's disease: a multicentre study with 4 years follow-up.
Rodriguez-Oroz MC; Obeso JA; Lang AE; Houeto JL; Pollak P; Rehncrona S; Kulisevsky J; Albanese A; Volkmann J; Hariz MI; Quinn NP; Speelman JD; Guridi J; Zamarbide I; Gironell A; Molet J; Pascual-Sedano B; Pidoux B; Bonnet AM; Agid Y; Xie J; Benabid AL; Lozano AM; Saint-Cyr J; Romito L; Contarino MF; Scerrati M; Fraix V; Van Blercom N
Brain; 2005 Oct; 128(Pt 10):2240-9. PubMed ID: 15975946
[TBL] [Abstract][Full Text] [Related]
33. Falls in Parkinson's disease. Causes and impact on patients' quality of life.
Michałowska M; Fiszer U; Krygowska-Wajs A; Owczarek K
Funct Neurol; 2005; 20(4):163-8. PubMed ID: 16483454
[TBL] [Abstract][Full Text] [Related]
34. Current controversies: levodopa in the treatment of Parkinson's disease.
Sharma JC; Vassallo M; Ross IN
Mov Disord; 2005 May; 20(5):642-3; author reply 643-4. PubMed ID: 15732129
[No Abstract] [Full Text] [Related]
35. Effect of subthalamic deep brain stimulation on the function of the urinary bladder.
Seif C; Herzog J; van der Horst C; Schrader B; Volkmann J; Deuschl G; Juenemann KP; Braun PM
Ann Neurol; 2004 Jan; 55(1):118-20. PubMed ID: 14705120
[TBL] [Abstract][Full Text] [Related]
36. Treatment of Parkinson's disease in Spain.
Grandas F; Kulisevsky J
Mov Disord; 2003 Jan; 18(1):87-9. PubMed ID: 12518304
[TBL] [Abstract][Full Text] [Related]
37. Ten-year follow-up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa.
Hauser RA; Rascol O; Korczyn AD; Jon Stoessl A; Watts RL; Poewe W; De Deyn PP; Lang AE
Mov Disord; 2007 Dec; 22(16):2409-17. PubMed ID: 17894339
[TBL] [Abstract][Full Text] [Related]
38. [Improvements in motor and non-motor symptoms in parkinson patients under ropinirole therapy].
Buchwald B; Angersbach D; Jost WH
Fortschr Neurol Psychiatr; 2007 Apr; 75(4):236-41. PubMed ID: 17427044
[TBL] [Abstract][Full Text] [Related]
39. Levodopa: management of Parkinson's disease.
Mov Disord; 2002; 17 Suppl 4():S23-37. PubMed ID: 12211137
[No Abstract] [Full Text] [Related]
40. Parkinson's goal: ease symptoms, slow progression.
Johns Hopkins Med Lett Health After 50; 2006 Jun; 18(4):4-5. PubMed ID: 16795901
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
